Genentech reported new real-world data from the prospective VOYAGER study at the EURETINA 2026 meeting in Vienna, Austria, this week, showing visual and anatomic outcomes with Vabysmo (faricimab-svoa) in patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

VOYAGER includes more than 5,000 patients across 28 countries and uses artificial intelligence and deep-learning algorithms to analyze spectral-domain optical coherence tomography images collected in clinical practice.

At 12 months, treatment-naïve eyes with nAMD gained a mean 4.6 ETDRS letters, while previously treated eyes had a mean change of -0.1 letters. Central subfield thickness (CST) decreased by 110.5 µm and 26.1 µm, respectively. In DME, treatment-naïve and previously treated eyes gained 8.2 and 2.7 letters, respectively, with CST reductions of 127.8 µm and 71.3 µm.

At 6 months, treatment-naïve eyes with branch RVO gained 10.0 letters, and those with central/hemi-RVO gained 16.6 letters. Previously treated eyes gained 2.0 and 3.9 letters, respectively. Reductions in subretinal and intraretinal fluid were observed across cohorts.

Genentech said fewer injections were administered during months 7 through 12 than during the first 6 months in the wet AMD and DME cohorts. The safety profile was generally consistent with that observed in phase 3 studies.